Changes in Beneficial Ownership · 4
Johnson & Johnson
JNJNYSEEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1787092263.xml
Filing details
- Report period
- 2026-08-17
- Issuer
- JOHNSON & JOHNSON
- Issuer CIK
- 0000200406
- Trading symbol
- JNJ
Reporting owner 1
- Name
- Taubert Jennifer L
- Reporting owner CIK
- 0001745938
- Relationship
- Officer
- Officer title
- EVP, WWC. Innovative Medicine
- Address
- ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-17 | M · Form 4 | 15,000 | A | 115.67 | 209,451.001 | D |
| Common Stock | 2026-08-17 | S · Form 4 | 15,000 | D | 263.36[F1] | 194,451.001 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Options (Right to Buy) | 115.67 | 2026-08-17 | M · Form 4 | 15,000 | D | 0 | 2020-02-13[F2] | 2027-02-13 | Common Stock | 15,000 | 28,712 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- This transaction was executed in multiple trades at prices ranging from $263.30 to $263.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
- F2
- Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable on the third anniversary of the grant date.↩ 1
Signature 1
- Signed
- /s/ Joleen Morgan, as attorney-in-fact for Jennifer Taubert
- Date
- 2026-08-18
Company context
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/.